Concepedia

Complement Therapeutic Resistance

Complement Therapeutic Resistance is a biological phenomenon characterized by the failure or diminished efficacy of complement-targeted therapies due to intrinsic or acquired mechanisms that prevent effective inhibition or modulation of the complement system.

15

Publications

999

Citations

124

Authors

50

Institutions

Publications per year

2017–2026

3

Parents

Publications

15

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Inger S. Nijhof, Tineke Casneuf, Jeroen van Velzen et al. · Blood · 2016 · 380 citations · Full text

, , +13

Progress and Trends in Complement Therapeutics

Daniel Ricklin, John D. Lambris · Advances in experimental medicine and biology · 2012 · 112 citations · Full text

, , +12

Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL

Odette Middleton, Emilio Cosimo, Edwina Dobbin et al. · Leukemia · 2014 · 78 citations

, , +14

Induced Resistance to Ofatumumab-Mediated Cell Clearance Mechanisms, Including Complement-Dependent Cytotoxicity, in Chronic Lymphocytic Leukemia

Nisar A. Baig, Ronald P. Taylor, Margaret A. Lindorfer et al. · The Journal of Immunology · 2014 · 53 citations · Full text

, , +17

Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity

Susanne Hörl, Zoltán Bánki, G. Carl Huber et al. · Leukemia · 2013 · 46 citations · Full text

, , +17

1–5 of 15

Authors

124

  1. RP
    Ronald P. Taylor

    University of Virginia, United States

    2 publications · 98 citations

    2

    h-index

  2. BL
    Betsy LaPlant

    Mayo Clinic, United States

    2 publications · 98 citations

    2

    h-index

  3. GS
    Grzegorz S. Nowakowski

    Mayo Clinic in Arizona, United States

    2 publications · 98 citations

    2

    h-index

  4. MA
    Margaret A. Lindorfer

    University of Virginia, United States

    2 publications · 98 citations

    2

    h-index

  5. NA
    Nisar A. Baig

    University of Virginia, United States

    2 publications · 98 citations

    2

    h-index

1–5 of 124

Institutions

50

  1. University of Virginia

    Charlottesville, United States

    2 h-index

    4 publications

    196 citations

  2. GlaxoSmithKline (United Kingdom)

    London, United Kingdom

    2 h-index

    3 publications

    168 citations

  3. Heidelberg University

    Heidelberg, Germany

    2 h-index

    7 publications

    264 citations

  4. German Cancer Research Center

    Heidelberg, Germany

    2 h-index

    3 publications

    96 citations

  5. Mayo Clinic in Arizona

    Scottsdale, United States

    2 h-index

    6 publications

    310 citations

  6. Mayo Clinic

    Rochester, United States

    2 h-index

    9 publications

    461 citations

  7. GlaxoSmithKline (United States)

    Philadelphia, United States

    1 h-index

    1 publications

    12 citations

  8. Royal Alexandra Hospital

    Paisley, United Kingdom

    1 h-index

    1 publications

    78 citations

1–8 of 50

Venues

  1. Blood

    5 publications · 472 citations

    5

    h-index

  2. Leukemia

    2 publications · 124 citations

    2

    h-index

  3. Leukemia & lymphoma/Leukemia and lymphoma

    1 publications · 45 citations

    1

    h-index

  4. Oncotarget

    1 publications · 29 citations

    1

    h-index

  5. Blood Advances

    1 publications · 45 citations

    1

    h-index

1–5